Edition:
United States

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

18.60USD
4:00pm EDT
Change (% chg)

$0.35 (+1.92%)
Prev Close
$18.25
Open
$18.15
Day's High
$18.60
Day's Low
$18.15
Volume
187,735
Avg. Vol
208,892
52-wk High
$20.85
52-wk Low
$8.68

Latest Key Developments (Source: Significant Developments)

Alder Biopharma Q4 Loss Per Share $0.80
Monday, 26 Feb 2018 04:14pm EST 

Feb 26 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS.Q4 LOSS PER SHARE $0.80.‍BIOLOGICS LICENSE APPLICATION (BLA) ON TRACK FOR SUBMISSION IN 2H18​.  Full Article

Alder Announces $250 Million Committed Equity Financing
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER ANNOUNCES $250 MILLION COMMITTED EQUITY FINANCING.ALDER BIOPHARMACEUTICALS INC - INVESTORS TO PURCHASE UP TO $250 MILLION OF NON-VOTING CLASS A PREFERRED STOCK DURING 3-YEAR TERM OF AGREEMENT.ALDER BIOPHARMACEUTICALS INC - TO USE NET PROCEEDS TO FUND PAYMENTS UNDER ALDER'S EUROPEAN PATENT SETTLEMENT.ALDER BIOPHARMACEUTICALS INC - TO ALSO USE PROCEEDS FOR EPTINEZUMAB INFUSION COMMERCIALIZATION-READINESS ACTIVITIES.  Full Article

Alder Biopharmaceuticals Enters Into European Patent Settlement, Global License Agreement With Teva
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER BIOPHARMACEUTICALS® ENTERS INTO EUROPEAN PATENT SETTLEMENT AND GLOBAL LICENSE AGREEMENT WITH TEVA IN THE FIELD OF ANTI-CGRP-BASED THERAPY.ALDER BIOPHARMACEUTICALS INC - ‍ALDER HAS AGREED TO MAKE AN IMMEDIATE ONE-TIME PAYMENT OF $25 MILLION TO TEVA​.ALDER BIOPHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, ALDER HAS AGREED TO WITHDRAW ITS APPEAL BEFORE EUROPEAN PATENT OFFICE.ALDER BIOPHARMACEUTICALS - UNDER TERMS CO AGREED TO PAY $75 MILLION AT EACH OF TWO SALES-RELATED MILESTONES FOLLOWING COMMERCIAL LAUNCH OF EPTINEZUMAB.ALDER SAYS UNDER TERMS CO AGREED TO PROVIDE CERTAIN ROYALTY PAYMENTS ON NET SALES AT RATES FROM 5% TO 7% FOLLOWING COMMERCIAL LAUNCH OF EPTINEZUMAB.ALDER - UNDER TERMS CO AGREED TO MAKE SECOND ONE-TIME PAYMENT OF $25 MILLION UPON APPROVAL OF BLA FOR EPTINEZUMAB WITH U.S. FDA.  Full Article

Alder Says Eptinezumab Met Primary Endpoint In Pivotal Phase 3 Promise 2 Clinical Trial
Monday, 8 Jan 2018 07:30am EST 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER ANNOUNCES EPTINEZUMAB SIGNIFICANTLY REDUCES MIGRAINE RISK MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PIVOTAL PROMISE 2 PHASE 3 TRIAL FOR CHRONIC MIGRAINE PREVENTION.ALDER BIOPHARMACEUTICALS INC - ANNOUNCED THAT EPTINEZUMAB, MET PRIMARY ENDPOINT IN ITS PIVOTAL PHASE 3 PROMISE 2 CLINICAL TRIAL.ALDER BIOPHARMACEUTICALS INC - ‍15% OF PATIENTS HAD NO MIGRAINES FOR A FULL THREE MONTHS​.ALDER BIOPHARMACEUTICALS INC - IN ADDITION, EPTINEZUMAB MET ALL KEY SECONDARY ENDPOINTS WITH VERY HIGH STATISTICAL SIGNIFICANCE.ALDER BIOPHARMACEUTICALS INC - ‍SAFETY AND TOLERABILITY WERE SIMILAR TO PREVIOUSLY REPORTED EPTINEZUMAB STUDIES​.ALDER BIOPHARMACEUTICALS INC - PLANS TO SUBMIT A BLA TO U.S. FDA FOR EPTINEZUMAB IN H2 OF 2018.  Full Article

Alder Biopharmaceuticals Q3 loss per share $0.92
Tuesday, 7 Nov 2017 04:23pm EST 

Nov 7 (Reuters) - Alder Biopharmaceuticals Inc :Alder biopharmaceuticals announces third quarter 2017 financial and operating results.Q3 loss per share $0.92.Q3 earnings per share view $-1.17 -- Thomson Reuters I/B/E/S.Alder Biopharmaceuticals Inc - ‍eptinezumab biologics license application (BLA) submission on track for 2h18​.Alder Biopharmaceuticals Inc - ‍promise 2 pivotal trial completed enrollment and top-line data on track for 1h18​.Alder-Sees available cash & cash equivalents, short-term investments to be sufficient for projected requirements through late 2018/early 2019​‍​.  Full Article

Alder Biopharmaceuticals Q2 loss per share $1.48
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Alder Biopharmaceuticals Inc :Alder Biopharmaceuticals announces second quarter 2017 financial and operating results.Q2 loss per share $1.48.Q2 earnings per share view $-1.61 -- Thomson Reuters I/B/E/S.  Full Article

Alder Biopharmaceuticals says public offering of 15 mln common shares priced at $10 per share
Wednesday, 12 Jul 2017 06:54pm EDT 

July 12 (Reuters) - Alder Biopharmaceuticals Inc :Alder biopharmaceuticals, inc. Prices public offering of common stock.Says public offering of 15.0 million common shares priced at $10.00per share.  Full Article

Alder Biopharmaceuticals announces commencement of public offering of common stock
Tuesday, 11 Jul 2017 04:28pm EDT 

July 11 (Reuters) - Alder Biopharmaceuticals Inc :Alder Biopharmaceuticals, Inc. announces commencement of public offering of common stock.Alder Biopharmaceuticals Inc - Intends to offer and sell, 12.5 million shares of its common stock in an underwritten public offering.Alder Biopharmaceuticals - Intends to use net proceeds from offering, to fund continued development of eptinezumab, among the others.  Full Article

Alder Biopharmaceuticals announces positive eptinezumab phase 3 results
Tuesday, 27 Jun 2017 07:00am EDT 

June 27 (Reuters) - Alder Biopharmaceuticals Inc :Alder Biopharmaceuticals announces positive eptinezumab phase 3 results for prevention of frequent episodic migraine.Says ‍​pivotal promise 1 top-line results show eptinezumab met primary and key secondary endpoints.Says beginning day 1 after first dose, significant reduction in proportion of patients experiencing migraine.Says average of 1 in 5 patients had no migraines in any given month over months 1 through 6.Says Promise 1 met the primary endpoint, that is highly statistically significant reductions in monthly migraine days.enrollment is on track for Promise 2; remains on track to submit BLA with FDA in second half of 2018.  Full Article

Alder Biopharmaceuticals says presentation of positive data from Phase 2B clinical trial evaluating Eptinezumab for prevention of migraine
Friday, 28 Apr 2017 01:24pm EDT 

April 28 (Reuters) - Alder Biopharmaceuticals Inc :Eptinezumab emerging clinical profile suggests migraine preventative benefit achieved as soon as 24-48 hours after single infusion.Single administration of Eptinezumab showed safety profile similar to placebo; no serious adverse events deemed treatment related.Alder Biopharmaceuticals Inc announces presentation of positive data from phase 2b clinical trial evaluating eptinezumab for prevention of migraine.  Full Article

BRIEF-Alder Biopharmaceuticals Reports Q1 Loss Per Share Of $1.73

* ALDER BIOPHARMACEUTICALS® REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS